FDA approves adjuvant atezolizumab for MRD-positive muscle-invasive bladder cancer, says Dr. Hafron
read at onclive ↗ApprovalPositive
The U.S. Food and Drug Administration has granted approval for adjuvant atezolizumab in patients with MRD-positive muscle-invasive bladder cancer.
The decision expands the use of the immunotherapy beyond its earlier indications, providing a new option for patients who have minimal residual disease after surgery.
Dr. Jason Hafron noted that targeting MRD could improve outcomes and lower the risk of cancer recurrence.
source
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “Dr Hafron on the FDA Approval of Adjuvant Atezolizumab in MRD+ MIBC”
read at onclive ↗
comments(0)
5-min edit window · permanent after that